Browse by author
Lookup NU author(s): Professor Farhad Kamali,
Dr David Ball,
Emeritus Professor Robin Seymour
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
The potential effect of co-medication with phenobarbitone, primidone and carbamazepine on plasma and saliva concentrations of 5-(4-hydroxyphenyl)-5-phenylhydantoin (4-HPPH), the major metabolite of phenytoin in man and on the incidence of phenytoin-induced gingival overgrowth was investigated in a group of 36 adult epileptic patients. There were no signifiant differences in plasma or saliva concentrations of 4-HPPH or phenytoin in patients prescribed phenytoin alone, compared to those who received phenytoin with either phenobarbitone, primidone, or carbamazepine. In addition, the extent and the incidence of gingival overgrowth were similar in the 2 groups. The results suggest that chronic comedication with other anti-convulsant drugs which induce phenytoin metabolism, does not affect the plasma or saliva 4-HPPB steady-state levels, nor the degree of gingival overgrowth in adult epileptic patients on therapy with phenytoin. © Munksgaard, 1999.
Author(s): Kamali F, McLaughlin WS, Ball DE, Seymour RA
Publication type: Article
Publication status: Published
Journal: Journal of Clinical Periodontology
Print publication date: 01/12/1999
ISSN (print): 0303-6979
ISSN (electronic): 1600-051X
Publisher: Wiley-Blackwell Publishing, Inc.
PubMed id: 10599907
Altmetrics provided by Altmetric